التفاصيل البيبلوغرافية
| العنوان: |
Proteomic changes related to actin cytoskeleton function in the skin of vildagliptin-treated mice. |
| المؤلفون: |
Nätynki, Antti1 (AUTHOR), Kokkonen, Nina1 (AUTHOR), Tuusa, Jussi1 (AUTHOR), Ohlmeier, Steffen2 (AUTHOR), Bergmann, Ulrich2 (AUTHOR), Tasanen, Kaisa1 (AUTHOR) kaisa.tasanen@oulu.fi |
| المصدر: |
Journal of Dermatological Science. Mar2024, Vol. 113 Issue 3, p121-129. 9p. |
| مصطلحات موضوعية: |
*BULLOUS pemphigoid, *CYTOSKELETON, *PROTEOMICS, *ORGANELLE formation, *CD26 antigen, *CELL motility, *CYTOSKELETAL proteins |
| مستخلص: |
Vildagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i) is a widely used type 2 diabetes medication that is associated with an up-to 10-fold increased risk for the development of bullous pemphigoid (BP), an autoimmune skin disease. The mechanism by which vildagliptin promotes the development of BP remains unknown. To elucidate effects of vildagliptin treatment on the mouse cutaneous proteome. We analyzed the cutaneous proteome of nondiabetic mice treated for 12 weeks with vildagliptin using label-free shotgun mass spectrometry (MS), two-dimensional difference gel electrophoresis (2D-DIGE), immunohistochemistry, immunoblotting, and quantitative real-time polymerase chain reaction. Although vildagliptin treatment did not cause any clinical signs or histological changes in the skin, separate MS and 2D-DIGE analyses revealed altered cutaneous expression of several proteins, many of which were related to actin cytoskeleton remodeling. Altogether 18 proteins were increased and 40 were decreased in the vildagliptin-treated mouse skin. Both methods revealed increased levels of beta-actin and C->U-editing enzyme APOBEC2 in vildagliptin-treated mice. However, elevated levels of a specific moesin variant in vildagliptin-treated animals were only detected with 2D-DIGE. Immunohistochemical staining showed altered cutaneous expression of DPP-4, moesin, and galectin-1. The changed proteins detected by MS and 2D-DIGE were linked to actin cytoskeleton remodeling, transport, cell movement and organelle assembly. Vildagliptin treatment alters the cutaneous proteome of nondiabetic mice even without clinical signs in the skin. Cytoskeletal changes in the presence of other triggering factors may provoke a break of immune tolerance and further promote the development of BP. • No clinical signs of adverse effects on vildagliptin-treated mice. • Cutaneous proteomic changes detected in vildagliptin-treated nondiabetic mice. • Vildagliptin exposure elevates proteins that are linked to actin. • Vildagliptin exposure decreases cytoskeleton-interacting proteins. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
